Loading
Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes.
Site: Breast (all subtypes) (shared total; subtype split not reported). World: 2,296,840 new cases a year.
| # | Country | New cases | Incidence ASR |
|---|---|---|---|
| 1 | China | 357,161 | |
| 2 | United States of America | 274,375 | |
| 3 | India | 192,020 | |
| 4 | Brazil | 94,728 | |
| 5 | Japan | 91,916 | |
| 6 | Russian Federation | 78,839 | |
| 7 | Germany | 74,016 | |
| 8 | Indonesia | 66,271 | |
| 9 | France (metropolitan) | 65,659 | |
| 10 | United Kingdom | 58,756 |
GLOBOCAN reports breast cancer as one site. HER2+ disease is roughly 15-20% of cases; the figures shown are for all breast cancer.
Country-level death counts mix every stage, subtype and year of diagnosis, and reflect access to screening and treatment as much as the disease. Survival differs by stage, subtype and year; the cancer page above leads with what can be done.
| # | Country | New cases | Deaths |
|---|---|---|---|
| 1 | China | 357,161 | 74,986 |
| 2 | United States of America | 274,375 | 42,900 |
| 3 | India | 192,020 | 98,337 |
| 4 | Brazil | 94,728 | 22,189 |
| 5 | Japan | 91,916 | 17,638 |
| 6 | Russian Federation | 78,839 | 22,115 |
| 7 | Germany | 74,016 | 20,601 |
| 8 | Indonesia | 66,271 | 22,598 |
| 9 | France (metropolitan) | 65,659 | 14,739 |
| 10 | United Kingdom | 58,756 | 12,122 |
World: 2,296,840 new cases and 666,103 deaths a year (GLOBOCAN 2022).
Waiting-time standards, the specialist centres, what NICE and the SMC fund by line of treatment, the National Genomic Test Directory codes, the trials open in the UK and the differences across the four nations.
| France | none recorded | 0 | 1,862 | 31,707 | #6 | ||
Milan · cancer center Programme: Breast surgery, Breast medical oncology | Italy | none recorded | 2 | 1,252 | 21,584 | #11 | |
Tokyo · government | Japan | none recorded | 0 | 1,599 | 21,937 | none recorded | #13 |
Barcelona · cancer center Programme: Breast ADC trials (Cortés) | Spain | none recorded | 2 | 967 | 23,548 | none recorded | #28 |
Stanford · university | United States | 0 | 3,016 | 50,896 | #30 | ||
Beijing · cancer center | China | none recorded | 0 | 365 | 3,800 | none recorded | #50 |
London · research institute | United Kingdom | none recorded | 4 | 637 | 10,594 | none recorded | - |
Washington, DC · cancer center Programme: Breast cancer (CLEOPATRA) | United States | 1 | 485 | 7,604 | - | ||
London · consortium | United Kingdom | none recorded | 1 | not matched | - | none recorded | - |
Los Angeles · cancer center | United States | 0 | 2,039 | 33,523 | - | ||
Dallas, TX · cancer center | United States | 0 | 1,744 | 19,757 | - | ||
Miami, FL · cancer center | United States | 0 | 1,607 | 15,145 | - | ||
Utrecht · cancer center | Netherlands | none recorded | 0 | 1,422 | 20,323 | - | |
Vienna · cancer center Programme: Austrian Breast and Colorectal Cancer Study Group | Austria | none recorded | 0 | 1,369 | 18,391 | - | |
Beijing · cancer center | China | none recorded | 0 | 1,344 | 18,195 | - |
These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with HER2-positive breast cancer but is thinly recorded here will look small.
Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.
20 centres are named on one of the types below rather than on HER2-positive breast cancer itself. Grouped by the type that holds them; the full table for each sits on that type's page.